HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Soaring incidence of young-onset colorectal cancer raises questions about screening, treatment
• Eribulin improves survival for patients with advanced liposarcoma, leiomyosarcoma
• Institution appoints neurosurgery chair
• Foolishness in medicine: Ignoring cigarette smoking, obesity in favor of prostate cancer screening Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• FDA approves Adynovate for hemophilia A
• FDA approves Opdivo for advanced renal cell carcinoma
• FDA approves Portrazza for advanced squamous NSCLC
• FDA approves Tagrisso for NSCLC
• FDA approves Darzalex for pretreated, refractory multiple myeloma
• FDA approves Ninlaro for previously treated myeloma
• FDA approves Opdivo for advanced, treatment-naive BRAF wild-type melanoma
• Active surveillance for small papillary thyroid cancers should be used with caution
• Active surveillance safe for favorable-risk prostate cancer
• Active surveillance should be standard for favorable-risk prostate cancer
• Advanced care planning rates increase modestly among patients with cancer
• ASCO updates guidelines on hematopoietic colony-stimulating factors
• Biomarkers predicted severity of GVHD after allogeneic HSCT
• Cancer diagnosis may encourage smoking cessation
• Comorbidities may have greater OS impact in CML than the malignancy
• Oxaliplatin pre-, post-surgery extends DFS for patients with advanced rectal cancer
• Cost of multiple myeloma treatment may cause ‘financial toxicity’
• Despite fewer smokers, poor screening criteria may raise lung cancer mortality
• Early post-chemotherapy discharge may be safe, cost-effective for patients with AML, MDS
• Early SLNB may worsen melanoma-specific survival, DFS
• Email alerts reduce unnecessary antibiotic use in cancer patients
• Epstein-Barr virus DNA may predict treatment efficacy for advanced nasopharyngeal cancer
• Families with children receiving cancer treatment may experience basic unmet needs
• Gross total resection improves outcomes for pediatric high-grade gliomas, especially among females
• High-dose selenium supplementation may increase risk for prostate cancer mortality
• Hormonal drugs for prostate cancer increase risk, incidence of cardiovascular events
• Ibrutinib safe, effective in previously treated Waldenström’s macroglobulinemia
• Incidence of high-grade cervical lesions has declined due to screening, vaccination
• Ipilimumab confers long-term survival in advanced melanoma
• Matched tumor analyses leads to more accurate diagnoses
• Mohs micrographic surgery for melanoma increased from 2003 to 2008
• No link between statin use, increased OS in colorectal cancer
• Noninvasive prenatal testing may detect presymptomatic cancers in pregnant women
• Oxaliplatin pre-, post-surgery extends DFS for patients with advanced rectal cancer
• Palliative chemotherapy fails to improve quality of life near death
• Primary chemotherapy noninferior to surgery in advanced ovarian cancer
• Prostate cancer diagnosis rates significantly decrease following USPSTF guideline revision
• Prostate cancer incidence, screening have declined following USPSTF recommendations
• Prostate cancer screening has declined in older men following guideline revisions
• Regional nodal irradiation yields marginal benefit for early-stage breast cancer
• Residential pesticide exposure may increase risk for pediatric blood cancers
• Ruxolitinib superior to standard therapy for polycythemia vera
• Salpingectomy may reduce risk for ovarian cancer
• Somatic driver mutation pattern in NSCLC varies by race
• TAS-102 significantly improves OS in refractory colorectal cancer
• Venous insufficiency symptoms predict thrombosis in older patients
• Weight cycling does not increase cancer risk
• Workplace factors influence bladder cancer incidence, mortality risks
• Hospice care reduced end-of-life costs, hospitalizations for Medicare beneficiaries
• American College of Radiation Oncology elects president
• Former Yale Cancer Center director to lead MGH physicians group
• Israel Cancer Research Fund honors City of Hope provost
• Lurie Comprehensive Cancer Center names associate director
• Medical association appoints president
• Memorial Sloan Kettering Cancer Center names department chairman
• Memorial Sloan Kettering surgeon elected board chair
• NCCN appoints interim VP of oncology research program
• Physician–scientist joins cancer center
• University of California, San Diego, names chair in urology
• Adjuvant capecitabine extends DFS among women with HER-2–negative, residual invasive disease
• Brentuximab vedotin stalled Hodgkin’s lymphoma progression after autologous HSCT
• Adding WATS3D to forceps biopsies improves detection of Barrett's esophagus, dysplasia
• Aspirin provides survival benefit as secondary preventative measure in colorectal cancer
• Aspirin reduces the risk for DVT in critically ill mechanically ventilated patients
• Bevacizumab plus chemotherapy improves OS in recurrent ovarian cancer
• Clinical, molecular characteristics predict Richter’s syndrome risk factors, outcomes
• Complete lymph node dissection does not improve survival after positive SLNB in melanoma
• Contrary to available evidence, PET imaging frequently used during NSCLC surveillance
• Gene therapy demonstrates clinical benefit for children with Wiskott-Aldrich syndrome
• Gene therapy shows promise for patients with chronic SCID-X1
• Genetically engineered T cells effective for B-cell malignancies post allogeneic HSCT
• G-Eye HD colonoscopy improves CRC screening, surveillance
• Higher mean dose intensity of ibrutinib may improve PFS in CLL
• Hispanics show lower survival vs. non-Hispanic whites for CRC
• HPV vaccine offers multisite protection, even among previously exposed women
• IFNA17, DOK3 genetic variants associated with increased incidence, severity of pediatric ITP
• Incidence of NSCLC has more than doubled among nonsmokers
• Late mortality rates have declined in pediatric cancer survivors
• Low-risk patients with VTE unlikely to bleed when assigned rivaroxaban
• Lymphovascular invasion, smoking history increase tumor recurrence in early-stage NSCLC
• Methylated DNA markers predict gastric cancer
• Mismatch repair deficiency predicts response to pembrolizumab in several cancer types
• Nivolumab yields superior OS in NSCLC compared with docetaxel
• Nivolumab-based treatments slow progression of melanoma
• Patient-reported feedback improves end-of-life care, reduces costs among patients with advanced cancers
• Pembrolizumab demonstrates efficacy in advanced head and neck cancers
• PRADA: Candesartan prevents LVEF decline in women treated for breast cancer
• Presence of CTCs 2 years post chemotherapy linked to poorer survival
• Prolonged red blood cell storage not linked to poorer transfusion outcomes
• Real-time protocol identifies high-risk pediatric B-ALL patients with favorable outcomes
• Researchers develop breast cancer risk model for Hispanic women
• Revised myeloma staging system serves as valuable predictor for survival
• Rivaroxaban antidote met all endpoints in phase 3 ANNEXA-R study
• Serum lactate dehydrogenase does not predict OS in myeloma
• Socioeconomic disparities in CRC death rate significantly affect national economy
• Speakers debate role of HDAC inhibitors in myeloma treatment
• Surgery for NSCLC varies significantly by race, geographic locations
• SVR improves overall survival, lowers risk of recurrence of HCC
• Targeting epigenetic switches may lead to novel therapies for B-cell lymphomas
• Warfarin transition appears tolerable in patients with cancer-associated thrombosis
• Women with luminal A breast cancer derive no benefit from adjuvant chemotherapy